HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Contracts For QRA Model To Determine Safe Use Levels For 26 Fragrance Allergens

This article was originally published in The Rose Sheet

Executive Summary

The ingredients at issue already must be labeled on cosmetic products in the EU due to their recognized sensitization and allergy potential. FDA expects to award the contract by the end of September, and finished work will be due to the agency within 18 months thereafter.

You may also be interested in...



FDA Moves Forward With Planned Cosmetic Allergy Survey, Defends Practical Utility, Statistical Power

Based on stakeholder comments, the FDA has made changes to the online questionnaire it plans to use to collect information from 1,000 consumers about adverse events they have experienced and believe were caused by allergens in cosmetic products. The agency remains confident that the pilot study will provide useful insight into cosmetic allergy prevalence in the US.

FDA Solicits Protocol For Assessing Cosmetic Ingredient Aggregate Exposure Risks

According to its May 16 notice, the agency intends to award the contract to NSF International. An FDA spokesperson said NSF already undertook related work for the agency in 2018 and has rendered similar services for the US Environmental Protection Agency.

CIR Expert Panel’s April Meeting: 82 Brown Algae Ingredients Reviewed; Preservative Developments; More

The Cosmetic Ingredient Review Expert Panel is taking its first look at brown algae-derived ingredients, with 32 passing muster at the panel’s April 8-9 meeting in Washington. Salicylic acid and fatty acids were among ingredients that received final safe verdicts, while four ingredient groups drew insufficient data announcements. Finally, parabens got tabled and MCI/MI was reopened for updates.

Related Content

Topics

UsernamePublicRestriction

Register

RS121798

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel